Correct Answer: B. Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation.
Losartan possesses a unique dual pharmacological action beyond simple angiotensin II receptor antagonism. The discriminating fact is that losartan is the only ARB with intrinsic thromboxane A₂ (TXA₂) antagonist activity, which distinguishes it from other ARBs like valsartan, irbesartan, and telmisartan. This TXA₂ antagonism occurs through a non-receptor-mediated mechanism and results in inhibition of platelet aggregation, providing an additional cardioprotective and antithrombotic benefit beyond blood pressure reduction. This property makes losartan particularly valuable in Indian patients with hypertension complicated by atherosclerotic disease or thrombotic risk. The mechanism is independent of AT₁ receptor blockade—it is an intrinsic property of the losartan molecule itself. This antiplatelet effect has been demonstrated in clinical studies and contributes to losartan's superior cardiovascular outcomes in certain patient populations. Unlike aspirin (which irreversibly inhibits COX), losartan's TXA₂ antagonism is reversible and occurs alongside its primary antihypertensive action, making it a dual-action agent in the ARB class.
Why the other options are wrong
A. The dose of candesartan should be reduced in mild-moderate liver failure but not in renal failure. — This is wrong because ARBs undergo minimal hepatic metabolism and do not require dose adjustment in hepatic failure. Candesartan is primarily eliminated unchanged in urine and bile; hepatic impairment does not significantly affect its clearance. However, renal failure does require dose reduction for candesartan. The statement reverses the actual pharmacokinetic requirement, making it a classic NBE trap that tests knowledge of ARB metabolism patterns. C. The dose of telmisartan should be reduced in renal failure but not in hepatic failure. — This is wrong because telmisartan is hepatically metabolized and does not require dose adjustment in renal failure. Telmisartan undergoes significant hepatic metabolism via glucuronidation and may accumulate in hepatic failure, potentially requiring dose reduction. The statement incorrectly suggests renal elimination is the primary route. This reversal of pharmacokinetic facts is a common NBE strategy to test depth of ARB metabolism knowledge. D. The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renal failure. — This is wrong because irbesartan does not require dose adjustment in either mild-moderate hepatic or renal failure. Irbesartan is hepatically metabolized but shows no clinically significant accumulation in mild-moderate liver disease. It is eliminated via both hepatic and renal routes with sufficient redundancy that neither organ dysfunction alone mandates dose reduction. This option tests whether students confuse irbesartan's metabolism with drugs that do require adjustment.
High-Yield Facts
- Losartan is the only ARB with intrinsic thromboxane A₂ antagonist activity independent of AT₁ blockade.
- ARB hepatic metabolism: Telmisartan (high hepatic metabolism), Losartan (moderate), Irbesartan (moderate), Candesartan (minimal)—only telmisartan requires caution in hepatic failure.
- ARB renal elimination: Candesartan requires dose reduction in renal failure; losartan, valsartan, irbesartan, and telmisartan do not require routine adjustment.
- Losartan's antiplatelet effect is reversible and non-competitive, distinct from aspirin's irreversible COX inhibition.
- Clinical advantage of losartan: Dual antihypertensive and antithrombotic action makes it preferred in Indian patients with CAD or stroke risk.
Mnemonics
ARB Metabolism: "TILT" Telmisartan (hepatic), Irbesartan (hepatic), Losartan (moderate), Telmisartan (repeat—high metabolism). Only telmisartan needs caution in liver disease. Use when comparing ARB dose adjustments. Losartan's Unique Property: "LOST in TXA₂" LOsartan is LOST (unique) in its TXA₂ antagonism—no other ARB has this. Helps students remember losartan ≠ other ARBs.
NBE Trap
NBE pairs ARB dose adjustments with organ failure to test whether students confuse hepatic vs. renal elimination routes. The trap is reversing which ARBs need adjustment in which organ failure (e.g., suggesting candesartan needs hepatic adjustment when it actually needs renal adjustment). Option B avoids this trap entirely by testing a unique pharmacological property rather than metabolism.
Clinical Pearl
In Indian hypertensive patients with concurrent CAD or prior stroke, losartan is often preferred over other ARBs precisely because its TXA₂ antagonism provides dual cardioprotection—blood pressure reduction plus antiplatelet benefit—without requiring additional aspirin in some cases, reducing GI bleed risk in elderly patients.
_Reference: KD Tripathi Pharmacology Ch. 28 (Antihypertensive Agents); Harrison Principles of Internal Medicine Ch. 246 (Hypertension)_